Sorafenib and dacarbazine in soft tissue sarcoma: A single institution experience

Expert Opinion on Investigational Drugs

Volumn 22, Issue 1, 2013, Pages 1-7

  Vincenzi, Bruno ^a   Silletta, Marianna ^a   Schiavon, Gaia ^b   Frezza, Anna Maria ^a   Del Vescovo, Raimondo ^a   Zobel, Bruno Beomonte ^a   Santini, Daniele ^a   Dei Tos, Angelo Paolo ^c   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Treviso General Hospital   (Italy)

Author keywords

Dacarbazine; Pre treated soft tissue sarcoma; Sorafenib

Indexed keywords

DACARBAZINE; SORAFENIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; MALE; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; RASH; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SARCOMA; TREATMENT OUTCOME;

EID: 84870980793     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.742886     Document Type: Article

References (23)

1. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcoma. J Clin Oncol 1987;5:840-50
2. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-406
3. Buesa JM, Mouridsen HT, van Oosterom AT, et al. High-dose DTIC in advanced sarcomas in the adult. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 1991;2:307-9
4. Hahn O, Stadler W. Sorafenib. Curr Opin Oncol 2006;18:615-21
5. Wilhelm SM, Carter C, Tang LY, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
6. Rahmani M, Davis EM, Bauer C, et al. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation ofMCL-1 through inhibition oftranslation. J Biol Chem 2005;280:35217-27
7. Escudier B, Eisen T, Stadler WM, TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
8. Llovet JM, Ricci S, Mazzaferro V, SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;24(359):378-90
9. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714-19
10. Ambrosini G, Cheema HS, Seelman S. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther 2008;Apr7(4):890-6
11. Peng CL, Guo W, Ji T, et al. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway. Cancer Biol Ther 2009;8(18):1729-36
12. Strumberg D, Richly H, Hilger RA. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23(5):965-72
13. Maki RG, D'Adamo DR, Keohan ML. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;Jul127(19):3133-40
14. McDermott DF, Sosman JA Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 2008;126(13):2178-85
15. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-47
16. Maruwge W, DArcy P, Folin A. Sorafenib inhibits tumor growth and vascularization of rhabdomyosarcoma cells by blocking IGF-1R-mediated signaling. Onco Targets Ther 2008;1 1:67-78
17. von Mehren M, Rankin C, Goldblum JR, et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012;1118(3):770-6
18. Bertuzzi A, Stroppa EM, Secondino S. Efficacy and toxicity of sorafenib monotherapy in patients with advanced soft tissue sarcoma failing anthracycline-based chemotherapy [abstract No:10025]. 2010 ASCO Annual Meeting
19. Pacey S, Ratain MJ, Flaherty KT, et al. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs 2011;29(3):481-8
20. ClinicalTrials.gov Identifier: NCT00837148. Available from: www. clinicaltrials.gov [Last access 18 June 2011]
21. DAdamo DR, Keohan ML, Carvajal RD, et al. A phase II trial ofsorafenib (S) and dacarbazine (D) in leiomyosarcoma (LMS), synovial sarcoma (SS), and malignant peripheral nerve sheath tumor (MPNST) [abstract No:10025]. 2011 ASCO Annual Meeting; 3-7 2011; Illinois, Chicago
22. Zucali PA, Bertuzzi A, Parra HJ, et al. The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs 2008;26(2):175-81
23. Garća-Del-Muro X, López-Pousa A, Maurel J, et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011;2029(18):2528-33